EF Hutton Reiterates Buy on CRISPR Therapeutics, Maintains $75 Price Target
Portfolio Pulse from Benzinga Newsdesk
EF Hutton analyst Tony Butler reiterates a Buy rating on CRISPR Therapeutics (NASDAQ:CRSP) and maintains a $75 price target.
June 09, 2023 | 2:53 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EF Hutton analyst Tony Butler reiterates a Buy rating on CRISPR Therapeutics and maintains a $75 price target.
The reiterated Buy rating and maintained price target by EF Hutton analyst Tony Butler indicates a positive outlook for CRISPR Therapeutics. This news is likely to have a positive impact on the stock price in the short term as it shows confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100